Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

Pharmacogenomics Journal

Volumn 14, Issue 3, 2014, Pages 241-247

  Yao, S ^a   Sucheston, L E ^a   Zhao, H ^b   Barlow, W E ^c   Zirpoli, G ^a   Liu, S ^a   Moore, H C F ^d   Thomas Budd, G ^d   Hershman, D L ^e   Davis, W ^a   Ciupak, G L ^a   Stewart, J A ^f   Isaacs, C ^g   Hobday, T J ^h   Salim, M ⁱ   Hortobagyi, G N ^b   Gralow, J R ^j   Livingston, R B ^k   Albain, K S ^l   Hayes, D F ^m   Ambrosone, C B ^a   more..

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SWOG STATISTICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Department of Medicine   (United States)

^f BAYSTATE MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

ⁱ Allan Blair Cancer Centre   (Canada)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

^l LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^m UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

more..

Author keywords

ALDH1A1; breast cancer; chemotherapy; pharmacogenetics; pharmacokinetics; toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ALDEHYDE DEHYDROGENASE; ALDH1A1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ABCB1 GENE; ABCC1 GENE; ADULT; ALDH1A1 GENE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER PATIENT; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTROINTESTINAL TOXICITY; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST NEOPLASMS; CLINICAL TRIAL; GENETICS; PHASE 3 CLINICAL TRIAL;

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84901268453     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.32     Document Type: Article

References (27)

1. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006; 98: 1108-1117.
2. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344: 1997-2008.
3. Choi JY, Nowell SA, Blanco JG, Ambrosone CB. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 2006; 7: 613-624.
4. Yao S, Maghsoudlou D, Ambrosone CB. Breast cancer pharmacogenetics in the era of personalized medicine. Curr Breast Cancer Rep 2012; 4: 271-281.
5. Sladek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 2002; 49: 309-321.
6. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008; 18: 1009-1015.
7. Lal S, Mahajan A, Chen WN, Chowbay B. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 2010; 11: 115-128.
8. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 2011; 130: 993-1002.
9. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS 2006.
10. Edlund CK, Lee WH, Li D, Van Den Berg DJ, Conti DV. Snagger: a user-friendly program for incorporating additional information for tagSNP selection. BMC Bioinformatics 2008; 9: 174.
11. The International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.
12. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
13. Luna A, Nicodemus KK. snp.plotter: an R-based SNP/haplotype association and linkage disequilibrium plotting package. Bioinformatics 2007; 23: 774-776.
14. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-391.
17. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103: 1916-1924.
18. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
19. Levi BP, Yilmaz OH, Duester G, Morrison SJ. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood 2009; 113: 1670-1680.
20. Khoury T, Ademuyiwa FO, Chandraseekhar R, Jabbour M, Deleo A, Ferrone S et al. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Modern Pathol 2012; 25: 388-397.
21. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008; 18: 515-523.
22. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL et al. SCAN: SNP and copy number annotation. Bioinformatics 2010; 26: 259-262.
23. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 2004; 63: 49-63.
24. Liu J, Zhou Z, Hodgkinson CA, Yuan Q, Shen PH, Mulligan CJ et al. Haplotypebased study of the association of alcohol-metabolizing genes with alcohol dependence in four independent populations. Alcohol Clin Exp Res 2011; 35: 304-316.
25. Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PC, Lee EJ et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008; 99: 816-823.
26. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754-3762.
27. Simon RM, Paik S, Hayes DF. Ues of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1-7.